Overexpression of B7-H3 Is Associated With Poor Prognosis in Laryngeal Cancer

Li, Yixuan; Cai, Qian; Shen, Xueyi; Rothenberg, Marc E.; Guan, Zhong

doi:10.3389/fonc.2021.759528

Cited by 7 publications

(7 citation statements)

References 37 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…B7-H3 is overexpressed in tumor tissues while its expression is low in normal tissues [25]. B7-H3 overexpression and its negative correlation with patient survival has been reported in various malignancies [17,[26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41]. Additionally, B7-H3 is expressed in immune cells; monocytes, dendritic cells, myeloid derived suppresser cells (MDSCs), neutrophils, macrophages, B cells, and activated T cells.…”

Section: The Distribution and Expression Of B7-h3 In Normal Tissues A...mentioning

confidence: 99%

New frontiers in immune checkpoint B7-H3 (CD276) research and drug development

et al. 2023

View full text Add to dashboard Cite

B7-H3 (CD276), a member of the B7 family of proteins, is a key player in cancer progression. This immune checkpoint molecule is selectively expressed in both tumor cells and immune cells within the tumor microenvironment. In addition to its immune checkpoint function, B7-H3 has been linked to tumor cell proliferation, metastasis, and therapeutic resistance. Furthermore, its drastic difference in protein expression levels between normal and tumor tissues suggests that targeting B7-H3 with drugs would lead to cancer-specific toxicity, minimizing harm to healthy cells. These properties make B7-H3 a promising target for cancer therapy.Recently, important advances in B7-H3 research and drug development have been reported, and these new findings, including its involvement in cellular metabolic reprograming, cancer stem cell enrichment, senescence and obesity, have expanded our knowledge and understanding of this molecule, which is important in guiding future strategies for targeting B7-H3. In this review, we briefly discuss the biology and function of B7-H3 in cancer development. We emphasize more on the latest findings and their underlying mechanisms to reflect the new advances in B7-H3 research. In addition, we discuss the new improvements of B-H3 inhibitors in cancer drug development.

show abstract

Section: The Distribution and Expression Of B7-h3 In Normal Tissues A...mentioning

confidence: 99%

New frontiers in immune checkpoint B7-H3 (CD276) research and drug development

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Quantitative analysis on the expression of B7-H3 in cancer tissues has been significantly associated with the T-stage, lymph node metastasis, and tumor node metastasis (TNM) stage (Fig. 1 ) [ 15 ]. Resistance to therapy is commonly encountered during anticancer treatment, along with changes in the tumor immune landscape and extracellular matrix re-organization preceding therapy resistance.…”

Section: B7-h3: An Overviewmentioning

confidence: 99%

B7-H3 at the crossroads between tumor plasticity and colorectal cancer progression: a potential target for therapeutic intervention

Varghese,

Samuel,

Brockmueller

et al. 2023

Cancer Metastasis Rev

View full text Add to dashboard Cite

B7-H3 (B7 homology 3 protein) is an important transmembrane immunoregulatory protein expressed in immune cells, antigen-presenting cells, and tumor cells. Studies reveal a multifaceted role of B7-H3 in tumor progression by modulating various cancer hallmarks involving angiogenesis, immune evasion, and tumor microenvironment, and it is also a promising candidate for cancer immunotherapy. In colorectal cancer (CRC), B7-H3 has been associated with various aspects of disease progression, such as evasion of tumor immune surveillance, tumor-node metastasis, and poor prognosis. Strategies to block or interfere with B7-H3 in its immunological and non-immunological functions are under investigation. In this study, we explore the role of B7-H3 in tumor plasticity, emphasizing tumor glucose metabolism, angiogenesis, epithelial-mesenchymal transition, cancer stem cells, apoptosis, and changing immune signatures in the tumor immune landscape. We discuss how B7-H3-induced tumor plasticity contributes to immune evasion, metastasis, and therapy resistance. Furthermore, we delve into the most recent advancements in targeting B7-H3-based tumor immunotherapy as a potential approach to CRC treatment.

show abstract

“…Issues related to delivery, toxicity and sustainability of B7-H3-targeted therapeutics in the central nervous system remain to be addressed in clinical trials [165]. Table 1 further summarizes the role of B7-H3 in other cancer types not mentioned above [99,[166][167][168][169][170][171][172].…”

Section: B7-h3 In Brain Tumorsmentioning

confidence: 99%

Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy

Zhao

Xia

et al. 2022

J Hematol Oncol

View full text Add to dashboard Cite

Immunotherapy for cancer is a rapidly developing treatment that modifies the immune system and enhances the antitumor immune response. B7-H3 (CD276), a member of the B7 family that plays an immunoregulatory role in the T cell response, has been highlighted as a novel potential target for cancer immunotherapy. B7-H3 has been shown to play an inhibitory role in T cell activation and proliferation, participate in tumor immune evasion and influence both the immune response and tumor behavior through different signaling pathways. B7-H3 expression has been found to be aberrantly upregulated in many different cancer types, and an association between B7-H3 expression and poor prognosis has been established. Immunotherapy targeting B7-H3 through different approaches has been developing rapidly, and many ongoing clinical trials are exploring the safety and efficacy profiles of these therapies in cancer. In this review, we summarize the emerging research on the function and underlying pathways of B7-H3, the expression and roles of B7-H3 in different cancer types, and the advances in B7-H3-targeted therapy. Considering different tumor microenvironment characteristics and results from preclinical models to clinical practice, the research indicates that B7-H3 is a promising target for future immunotherapy, which might eventually contribute to an improvement in cancer immunotherapy that will benefit patients.

show abstract

Overexpression of B7-H3 Is Associated With Poor Prognosis in Laryngeal Cancer

Cited by 7 publications

References 37 publications

New frontiers in immune checkpoint B7-H3 (CD276) research and drug development

New frontiers in immune checkpoint B7-H3 (CD276) research and drug development

B7-H3 at the crossroads between tumor plasticity and colorectal cancer progression: a potential target for therapeutic intervention

Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy

Contact Info

Product

Resources

About